Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
Completed
Quintiles, Inc.
Phase 2
2011-09-01
This study was designed to assess the safety and efficacy of multiple interferon-free
treatment regimens of sofosbuvir (Sovaldi™; GS-7977; PSI-7977) and GS-0938 (PSI-352938) alone
and in combination, with and without ribavirin (RBV). Each regimen was to be evaluated over
12 and 24 weeks to identify the optimal duration of therapy to maximize the benefit
(sustained virologic response [SVR]) versus risk (safety and resistance).
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
Completed
Gilead Sciences
Phase 2
2011-09-01
This study was designed to assess the safety and efficacy of multiple interferon-free
treatment regimens of sofosbuvir (Sovaldi™; GS-7977; PSI-7977) and GS-0938 (PSI-352938) alone
and in combination, with and without ribavirin (RBV). Each regimen was to be evaluated over
12 and 24 weeks to identify the optimal duration of therapy to maximize the benefit
(sustained virologic response [SVR]) versus risk (safety and resistance).
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
Completed
Gilead Sciences
Phase 3
2013-09-24
This study will assess the efficacy, safety, and tolerability of 16 or 24 weeks of sofosbuvir
(Sovaldi®; SOF) + ribavirin (RBV), and 12 weeks of SOF+RBV+ pegylated interferon (Peg-IFN) in
treatment-naive and treatment-experienced adults with chronic genotype 3 hepatitis C virus
(HCV) infection, and treatment-experienced adults with cirrhosis and chronic genotype 2 HCV
infection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
